This inventor holds 14 USPTO granted patents and 3 published patent applications and 5 EPO patents, primarily in Oligonucleotide Therapeutics. Top assignees: Antisense Pharma Gmbh, Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh, Biognostik Ges. Fur Biomolekulare Diagnostik Mbh. Active years: 2002-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Gottingen, DE (2008)
- Bovenden, DE (2002 - 2010)
- Göttingen, DE (2005 - 2014)
- Donaustauf, DE (2011 - 2014)
- Regensburg, DE (2015)
Company Filing History:
6 out of 10 
4 out of 4 
2 out of 2 Years Active: 2002-2015
Areas of Expertise:
Title: The Innovative Contributions of Karl-Hermann Schlingensiepen
Introduction
Karl-Hermann Schlingensiepen is a distinguished inventor based in Donaustauf, Germany. With a remarkable portfolio of 14 patents, he has significantly contributed to the fields of oligonucleotide modification and medical treatments. His innovative methods pave the way for advancements in therapeutic applications, particularly in oncology and immune responses.
Latest Patents
Among his latest patents, Schlingensiepen developed a method for selective oligonucleotide modification. This method involves producing a modified oligonucleotide by covalently binding at least one polymer, preferably polyalkylene oxide, to the 5'-end or the 3'-end of the oligonucleotide through native ligation. Notably, this polymer or compound is specified to be non-protein or peptide if only the 5'-end is modified. The invention furthers the potential of these modified oligonucleotides in creating medicaments aimed at preventing and treating various conditions, including tumors, immune diseases, cardiovascular disorders, and viral infections.
Another significant patent focuses on the dosage of oligonucleotides suitable for tumor treatment. This method details the intravenous administration of antisense oligonucleotides in a dosing range of 400 to 800 mg per treatment cycle. The antisense oligonucleotides are composed of 8 to 30 nucleotide building blocks that hybridize with mRNA of TGF-beta-2, -1 and/or -3, contributing to the preparation of a pharmaceutical composition for tumors.
Career Highlights
Karl-Hermann Schlingensiepen has held prominent positions in research and development within the biopharmaceutical industry. He has been associated with renowned companies such as Antisense Pharma GmbH and Biognostik Gesellschaft Für Biomolekulare Diagnostik mbH, where he focused on the innovative aspects of his patented technologies.
Collaborations
Throughout his career, Schlingensiepen has collaborated with notable individuals in his field, including Reimar Schlingensiepen and Wolfgang Brysch. These collaborations have undoubtedly fueled his inventive processes and expanded the impact of his work in medical diagnostics and therapeutics.
Conclusion
Karl-Hermann Schlingensiepen stands as a prominent figure in modern invention, particularly in medical biotechnology. His patents reflect a commitment to innovation that addresses critical health issues, showcasing his expertise and dedication to improving therapeutic solutions. Through his latest methods, Schlingensiepen continues to make strides that may significantly benefit patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile